Skip to content

Community-based Smoking Cessation Treatment for Adults With High Stress Sensitivity.

Efficacy and Implementation of Exercise-based Smoking Cessation Treatment for Adults With High Anxiety Sensitivity.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06053567
Acronym
STEP3
Enrollment
360
Registered
2023-09-25
Start date
2023-12-27
Completion date
2029-06-30
Last updated
2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nicotine Dependence

Brief summary

Anxiety sensitivity, reflecting the fear of bodily sensations, is a risk factor for the maintenance and relapse of smoking. This study is designed to address the question - is a smoking cessation intervention personalized to high anxiety sensitive smokers and adapted for implementation by the YMCA effective among racially/ethnically diverse samples?

Detailed description

This protocol provides the recommended treatment to achieve smoking cessation (i.e., counseling and nicotine replacement therapy) and randomly assigns individuals to a high-intensity exercise or low-intensity exercise intervention as a strategy to engage the mechanisms relevant to high anxiety sensitive smokers to improve smoking cessation outcomes.

Interventions

BEHAVIORALAerobic Exercise

Participants will select a YMCA branch and will be assigned a personal fitness instructor who will oversee a 15-week exercise intervention. The weekly exercise prescription is 75 minutes of aerobic training.

BEHAVIORALCounseling

Participants will receive the standard tobacco cessation package of up to 5 proactive interactions from the Texas Tobacco Quitline (TTQ). Interactions are typically phone calls, but can be chat or live text if the participant prefers. Interaction 1 is for assessment and quit date planning, Interaction 2 occurs prior to the quit date and can be a group session, Interaction 3 occurs shortly following the quit date, and Interactions 4 and 5 are for relapse prevention if the smoker has quit or problem solving if they have not quit. TTQ also offers a tobacco cessation text messaging program and access to a web portal with a variety of cessation resources.

DRUGNicotine patch

On the target quit day (week 6), participants will be provided 8 weeks of nicotine replacement therapy (24-hour transdermal nicotine patches \[TNP\]).

Sponsors

Jasper A. Smits
Lead SponsorOTHER
University of Houston
CollaboratorOTHER
University of Oklahoma
CollaboratorOTHER
National Cancer Institute (NCI)
CollaboratorNIH
YMCA
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult (age ≥ 18); * High Anxiety Sensitivity (≥5 on the Short Scale Anxiety Sensitivity Index \[SSASI\]); * Daily smoker, ≥5 cigarettes (including e-cigarettes, little cigars/cigarillos) for ≥1 year; * Motivated to quit smoking as evidenced by a score of ≥5 on a 0-10 Likert scale; * Body mass index \< 40; * Medical clearance to participate. * Located near a participating YMCA site (within 50 miles)

Exclusion criteria

* Regular exercise defined as engaging in vigorous-intensity exercise for at least 75 minutes per week for the last 3 months * Receiving current intervention for smoking cessation. * Outstanding debt to the YMCA * Listed as a sex offender on the National Sex Offender Registry

Design outcomes

Primary

MeasureTime frameDescription
7-day point prevalence abstinence (PPA) at 6-month follow-upProtocol week 30, which is 24 weeks (6 months) after the quit attempt (set at week 6)Self-report of no smoking (not even a puff) during the previous 7 days, verified by expired carbon monoxide (CO; ≤5ppm), saliva cotinine (\<30 ng/mL), or significant other, and not invalidated by any of these verification measures. Failure to provide any of these 3 verification measures will result in PPA being considered missing.

Secondary

MeasureTime frameDescription
7-day point prevalence abstinence (PPA) at 12-month follow-upProtocol week 54, which is 48 weeks (12 months) after the quit attempt (set at week 6)Self-report of no smoking (not even a puff) during the previous 7 days, verified by expired carbon monoxide (CO; ≤5ppm), saliva cotinine (\<30 ng/mL), or significant other, and not invalidated by any of these verification measures. Failure to provide any of these 3 verification measures will result in PPA being considered missing.
7-day point prevalence abstinence (PPA) at 9-month follow-upProtocol week 42, which is 36 weeks (9 months) after the quit attempt (set at week 6)Self-report of no smoking (not even a puff) during the previous 7 days, verified by expired carbon monoxide (CO; ≤5ppm), saliva cotinine (\<30 ng/mL), or significant other, and not invalidated by any of these verification measures. Failure to provide any of these 3 verification measures will result in PPA being considered missing.

Countries

United States

Contacts

CONTACTMarla I Sarmiento, BS
sarmimar@utexas.edu915-502-9979
PRINCIPAL_INVESTIGATORJasper Smits, PhD

University of Texas at Austin

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 16, 2026